The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental therapy called cintredekin besudotox (IL13-PE38QQR), which Precision Neuromed is…
Glioma
The experimental therapy iopofosine I 131Â may improve survival outcomes in children and young adults with hard-to-treat glioma, according to new clinical trial data announced…
The European Commission has approved Voranigo (vorasidenib) for certain types of glioma, marking the arrival of a new targeted pill poised to change…
Enrollment is now complete in a Phase 2b clinical trial testing Bpgbio’s BPM31510, a treatment candidate for glioblastoma multiforme (GBM), a rapidly progressing type…
The National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to include Modeyso (dordaviprone) as an appropriate option for a rare recurrent…
Researchers may have found a way to halt the spread of aggressive brain tumors by targeting the environment around the cancer cells. A new study…
Enrollment is now open in a U.S. clinical trial testing the immune-modulating therapy CUE-102 in people with recurrent glioblastoma, an aggressive form of glioma…
The U.S. Food and Drug Administration (FDA) will allow Hemispherian to test its first-in-class experimental therapy for glioblastoma in a Phase 1 clinical trial.
A committee of the European Medicines Agency (EMA) is recommending that the daily oral therapy Voranigo (vorasidenib) be approved in the European Union to treat…
A study found that analyzing levels of immune cells and related molecules in the bloodstream of people with glioma can accurately distinguish between different…
Recent Posts
- Infection risk shifts over time with both CAR T and bispecific antibody therapy
- Building the quiet architecture of a caregiving day
- New CAR T-cell therapy shows promise in tough myeloma cases
- CAR T-cell therapy before surgery boosts glioblastoma control in mice
- Gynecologic Cancer Awareness Month urges education, action, and support